FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials | Synapse
March 25, 2026
FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials
Key Points
The aim is to explore the FDA's draft guidance on Bayesian methods in clinical trials.
Analysis of the FDA draft guidance document
Discussion of implications for therapeutic testing
Highlights the importance of Bayesian methods in clinical trials
Discusses potential benefits for evaluating new therapeutics
Abstract
This Perspective discusses the draft guidance for industry that the US Food and Drug Administration released on the use of bayesian methods in testing therapeutics.